The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | ZUMA-1 update: durable survival in R/R DLBCL patients treated with axi-cel
Here, Sattva Neelapu, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the two-year follow-up of the ZUMA-1 study (NCT02348216) assessing axicabtagene ciloleucel (axi-cel) in relapsed/refractory, diffuse large B-cell lymphoma (DLBCL) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Neelapu mentions that 51% of patients treated with axi-cel survived the two-year period, a fourfold increase compared to the historical median survival of six months.
